Form 4: Artivion SVP Marshall S. Stanton Reports Stock Transactions

Marshall S. Stanton, SVP of Clinical & MD Affairs at Artivion, Inc., reports the acquisition and disposal of company stock related to performance stock units.

Summary

• On March 6, 2025, Marshall S. Stanton, SVP of Clinical & MD Affairs at Artivion, Inc., acquired 19,240 shares of common stock related to performance stock units granted on February 23, 2024.
• One-third of these units vested on March 6, 2025, with the remaining shares vesting in two installments on February 23, 2026, and February 23, 2027, contingent upon continued employment.
• Also on March 6, 2025, Stanton sold 1,603 shares at $24.8042 per share to cover tax withholding obligations associated with the vesting of the performance stock units.
• Following these transactions, Stanton beneficially owns 115,880 shares of Artivion, Inc. common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as the transactions are routine and related to compensation.

Positives

• The vesting of performance stock units suggests that performance targets were met, which is a positive indicator.

Negatives

• The sale of shares to cover tax obligations, while routine, could be interpreted as a slight negative, although it's a standard practice.

Risks

• Future vesting of performance stock units is contingent upon continued employment, introducing a potential risk factor.

Future Outlook

The remaining performance stock units will vest on February 23, 2026, and February 23, 2027, contingent upon continued employment.

Industry Context

Insider transactions are closely monitored in the healthcare industry to ensure compliance with regulations and to provide transparency to investors.

Comparison to Industry Standards

• Similar transactions are common among executives in publicly traded companies, particularly those with equity-based compensation plans.
• Companies like Medtronic and Boston Scientific also utilize performance-based equity awards.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding executive compensation and ownership.

Next Steps

• Continued monitoring of insider transactions for any significant changes in ownership.

Key Dates